Loading…
Loading…
VDRM does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for VDRM and 80,000+ other tickers.
See exactly how VDRM's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for VDRM and 80,000+ other tickers.
ViaDerma, Inc., a specialty pharmaceutical enterprise based in the United States, focuses on both the development and commercialization of pharmaceutical products. It also licenses its proprietary technology to other companies within the pharmaceutical sector, addressing various therapeutic areas. The company's primary offering is Vitastem, a topical antibiotic containing tetracycline, effective for treating a broad spectrum of ailments such as cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. Beyond its established products, ViaDerma is dedicated to…
LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, today announced that it remains fully operational and is actively working to complete its overdue annual and quarterly financial reports.
LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a leader in innovative wound care solutions, is excited to announce that a shipment of 500,000 units of its flagship product, a tetracycline based topical antibiotic, has been in production and is being prepared for delivery to Nigeria before the end of August 2024. This marks a significant milestone in ViaDerma's ongoing efforts to expand its global footprint and provide effective wound care solutions across Africa.
LOS ANGELES, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), a leader in innovative wound care solutions, proudly announces the successful completion of pivotal distribution agreements across the Middle East and Eastern Europe. Dr. Christopher Otiko, President of ViaDerma, recently returned from the United Arab Emirates, where he met with representatives from two leading distribution companies in Dubai and finalized agreements centered around ViaDerma's flagship topical antibiotic product.
LOS ANGELES, June 06, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM) is pleased to announce that on May 13, 2024, the Company released its quarterly report for the period ending March 31, 2024. The report shows a 3700% increase of cash on hand over the same period last year rising from $9,933.00 to $377,901.
LOS ANGELES, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM) is pleased to announce several new and exciting business updates for current and prospective shareholders, customers, partners, and healthcare providers.